Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1
Franceska Kovaci, Cassandre Goachet, Simon Perrin, Lotfi Slimani, Fanny Coulpier, Françoise Tilotta, Piotr Topilko, Céline Colnot · 2025
Read Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1 by Franceska Kovaci, Cassandre Goachet, Simon Perrin, Lotfi Slimani, Fanny Coulpier, Françoise Tilotta, Piotr Topilko, Céline Colnot (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12706011.txt.
Description
Neurofibromatosis type 1 affects about one in 3,000 people and can bend the spine as well as grow tumors and bone defects. The eight authors use a mouse model in which the Nf1 gene is switched off in boundary cap cells, a neural crest subset, and their descendants. Micro-CT scans showed spine deformity from 12 months of age, with vertebral changes resembling those of patients.
Fate mapping traced the problem to osteoblasts from that lineage, which multiplied in the vertebrae. More Nf1-deficient cells meant more vertebral bone and worse kyphosis curvature. Treating the mice with inhibitors of the RAS-MAPK pathway prevented the deformity. The authors name those osteoblasts as the cellular origin of the spine defect and propose pathway blockade as a preventive strategy.
Catalog record
| CREATOR | Franceska Kovaci, Cassandre Goachet, Simon Perrin, Lotfi Slimani, Fanny Coulpier, Françoise Tilotta, Piotr Topilko, Céline Colnot |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |